GWS
ARCT icon

Glassman Wealth Services’s Arcturus Therapeutics ARCT Stock Holding History

Glassman Wealth Services’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1
Closed – – 1655
2022
Q1 		$0 Buy
+1
New +$26 ﹤0.01% 1625

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Glassman Wealth Services's ARCT Position: Q2 2022 in Review

Glassman Wealth Services sold out of Arcturus Therapeutics (ARCT) in Q2 2022, closing a stake of 1 share.

Glassman Wealth Services first reported a position in ARCT in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 128 funds tracked by Wall St. Rank hold ARCT as of Q2 2022.

  • Glassman Wealth Services reported no remaining Arcturus Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Glassman Wealth Services sold 1 Arcturus Therapeutics share in Q2 2022.
  • Glassman Wealth Services first reported a position in Arcturus Therapeutics in Q1 2022 and held it in 1 quarter.
  • Glassman Wealth Services's Arcturus Therapeutics position peaked at $0 in Q1 2022.
  • 128 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2022.

Based on Glassman Wealth Services's 13F filing for Q2 2022, filed 4 Aug 2022.